Podcasts about IV

Niko Moreno joins Jeremiah to discuss the Leg 2 of the Sounders Concacaf Champions Cup matchup against the Whitecaps. They review the 2-1 victory as well as talk about their experience in the Sounders home away from home, Spokane. To wrap things up, the two talk about Seattle's next league match away at Minnesota and finally share thoughts on the Sounders next round CCC opponents, Tigres of Liga MX.Follow Niko Moreno on BlueSky and YouTube.Sponsor

Meditación en el sábado de la IV semana de Cuaresma. El Evangelio nos presenta los diversos pareceres de los judíos sobre Jesús. Muchos de ellos ignoraban la verdad sobre el Señor: que había nacido en Belén, y no en Galilea, y eso les impedía creer en Él como Mesías. Necesitamos formarnos y estudiar para evitar la ignorancia, que es enemiga de la fe. Solo así amaremos a Dios con toda la mente.

In this episode, we take calls about: a guy who thought some chicken nuggets would prepare our caller for a special screening back at his place, someone who was asked to wear some strappy heels for a chicken nugget date, a drooly makeout with a guy who wouldn't take the hint, and we get a final update to the Jeans saga but make it live this time. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Judgies Merch is Available HERE!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 3:42 Nuggets and Dinosaur 17:39 Strappy Heels and Nuggets 26:08 Drooly Makeout 37:24 Jean Burns FINAL UPDATE Learn more about your ad choices. Visit megaphone.fm/adchoices

Meditación en el viernes de la IV semana de Cuaresma. En la primera lectura se lee: «Acechemos al justo, que nos resulta fastidioso: se opone a nuestro modo de actuar, nos reprocha las faltas (...) su sola presencia nos resulta insoportable». Estas palabras se cumplen en la escena que narra el Evangelio: la animadversión de algunos judíos contra Jesús. A veces la fe, la piedad o la vida limpia, pueden desatar la contradicción. Hemos de ser valientes para perseverar a pesar de ello.

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

Hoy hablaremos de las flores comestibles aprovechando que estamos a las puertas de la primavera; de Iván el Terrible, el zar que convirtió el miedo en herramienta de gobierno; del petróleo, ese “aceite de roca” que ya conocían en la antigüedad; y de Teherán, una megaciudad al pie de las montañas donde se cruzan smog, modernidad y viejas historias persas.See omnystudio.com/listener for privacy information.

In this episode, we review key updates from the 2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke, including changes to IV thrombolysis, antiplatelet therapy, endovascular treatment, blood pressure goals, and glycemic goals. Key Concepts Tenecteplase (TNKase) is now equally preferred to alteplase (Activase) by the 2026 AHA/ASA guidelines. Tenecteplase has several advantages related to administration and the risk of medication errors. IV thrombolysis can be given in selected patients up to 9 hours after stroke symptom onset depending on brain imaging findings. Patients with symptom onset less than 4.5 hours are still eligible for IV thrombolysis regardless of brain imaging findings. IV thrombolysis should not be given for mild, non-disabling stroke symptoms. A "non-disabling" stroke means the symptoms do not impair activities of daily living or ability to return to work. The criteria for dual antiplatelet therapy (DAPT) has been updated. DAPT can be given for NIHSS of 4 or 5 (not just 3 or less) and can be started up to 72 hours after stroke onset (not just within 24 hours). References Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. Published online January 26, 2026. doi:10.1161/STR.0000000000000513

Sobre las claves detrás del retiro masivo de decretos de Contraloría por parte del Gobierno y las negociaciones secretas de EE.UU. con el castrismo, en medio de las advertencias de Donald Trump, Iván Valenzuela conversó con las editoras Andrea Vial y Angélica Bulnes en un nuevo Rat Pack de Mesa Central.

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversaron con Rodrigo Álvarez y Allan Álvarez sobre el complejo escenario económico y político provocado por el alza histórica en el precio de los combustibles.

In the second part of this series, Dr. Tesha Monteith and Dr. Jennifer Robblee discuss updates to the emergency room recommendations for the acute treatment of migraines.  Show citations:  Robblee J, Minen MT, Friedman BW, Cortel-LeBlanc MA, Cortel-LeBlanc A, Orr SL. 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2026;66(1):53-76. doi:10.1111/head.70016 Robblee J, Khan FA, Marmura MJ, et al. Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method. Cephalalgia. 2025;45(9):3331024251367767. doi:10.1177/03331024251367767 Show transcript:  Dr. Tesha Monteith:   Hi, this is Tesha Monteith with the Neurology Minute. I've just been speaking with Jennifer Robblee about her exciting work, defining refractory migraine with an international consensus, as well as her work with the American Headache Society on a guideline update for parental pharmacotherapies for migraine in the emergency department. So Jennifer, we've just been chatting on the podcast about all the great work out of the American Headache Society, updating the emergency room recommendations for acute treatment of migraine. Can you give a summary of those findings? Dr. Jennifer Robblee:  We looked at all of the new data for randomized control trials in the emergency room. We found 26 new trials, and several of those were actually a class one study that we felt had a low risk of bias. And from that, we applied the grading. So we actually have two grade A medications where it is that you must offer, of course, to the appropriate patient. And that's prochlorperazine IV, and greater occipital nerve blocks. Now, there's also a grade A must not offer, and that's IV hydromorphone. Then we have some grade B, which is should offer, and that's dexketoprofen, ketorolac, metaclopramide, sumatriptan subcutaneous, and supraorbital nerve blocks. So really exciting that we have lots of things that we can now say we have pretty good evidence or very good evidence to offer them to our patients. Dr. Tesha Monteith:  Great. It's always nice to see this update based on evidence. Dr. Jennifer Robblee:  Yes, I think it's so important, because right now when we see patients, and I'm sure you get this all the time, they come back, say they were in the emergency room for a severe headache and they got a migraine cocktail. And you're like, "Do you know what you were given?" And they say, "I don't know. I was just told it's a migraine cocktail." And as you know, that mean many, many different things. And when you are able to pull the records, it is many, many different things that a migraine cocktail can mean. So I'm hoping that this can start to standardize what we're actually giving our patients as we await more trials in the future that might start to tell us what that combo of treatments really should be. For right now, these at least tell us what individual treatments have the best evidence. Dr. Tesha Monteith:  Thanks so much, Jennifer.  

Meditación en el miércoles de la IV semana de Cuaresma. El Señor nos habla constantemente del Padre misericordioso. Y también el Antiguo Testamento es la historia de las misericordias de Dios con los hombres.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Meditación predicada en el Colegio Mayor Alcor el martes de la IV semana de Cuaresma, sobre el Evangelio del día, que recoge la escena de la curación del paralítico de la piscina de Betesda. ¡Treinta y ocho años manteniendo la esperanza de ser curado por Dios! También nosotros hemos de insistir con tozudez y esperanza en nuestras luchas, fiados en el poder del Señor.Escucha este episodio completo y accede a todo el contenido exclusivo de Meditaciones diarias. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/874295

Aaron joins Jeremiah to recap the win at San Jose and they come to the conclusion that it was good, actually, to win. They also talk Vancouver Whitecaps Leg 2 preview and express excitement about going to Spokane to play some soccer.Sponsor

Aaron joins Jeremiah to recap the win at San Jose and they come to the conclusion that it was good, actually, to win. They also talk Vancouver Whitecaps Leg 2 preview and express excitement about going to Spokane to play some soccer.Sponsor

L'IA vous fait griller le cerveau au travail, les robots arrivent officiellement sur le champ de bataille, et les conséquences de la guerre en Iran sur l’économie de la tech.  Me soutenir sur Patreon Me retrouver sur YouTube On discute ensemble sur Discord Interactions auditeurs Oyajuu : ton papa c'est root. Le MacBook Neo sera (un peu) réparable. Desert Storm III (ou IV ?) Iran pas les armes, où est l’Hélium de la situation ? 9 mois plus tard, un heureux évènement. Insoumis : Claude le woke contre Pitex7. Pro human déclaration : pourtant dans transpartisan, il y a “trans”… Chaos Computer Club L'IA a sa première tuerie de masse ! Avec Perplexity, maintenant c'est personnel. L’œil dans le rétro : Claude sécurise l'Apple II. Combien de stagiaires sous cocaïne pour gagner un million ? Retention Song Les apps IA sont des feux de paille ? Si c'est gratuit, c'est bientôt fini… Erreur de prédiction pour Oracle. Avocat ou Guacamole chez Meta ? Grocket league : exode, exil et exaspération exacerbée chez xAI. Jeux vidéo DLSS ou DLexcess? Le futur est arrivé trop vite. Finalement, c'est peut être pas une xbox. Participants Une émission préparée par Guillaume Poggiaspalla Présenté par Guillaume Vendé

Sobre la estrategia económica del Ejecutivo, que busca retomar la actividad con más de 50 medidas de emergencia, en medio de tensiones internas por beneficios a uniformados condenados del estallido, Iván Valenzuela conversó con Marily Lüders y Paula Valenzuela en un nuevo Rat Pack de Mesa Central.

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversaron con Isabel Plá y Tatiana Klima sobre el viaje del Presidente José Antonio Kast a Arica, la construcción de zanjas en la frontera y las posiciones que han tomado desde la oposición.

In this episode, we talk about: a bucket in a secret shed that has someone wondering what their uncle is up to, an oopsie on our end as we read a story about a snotty blowjob that we've read before, a guy who doesn't want to watch after his daughter but expects his wife to, a listener that had a medical mystery of loose air in their body, and a coworker that gets caught using their work's ChatGPT for erotica. We also go over if things are French or not in this week's Circle Jurdge. This episode is brought to you by: Home Chef! Go to ⁠homechef.com/judgies⁠ for 50% off your first box and free desert for life! Vote for the JPAs Here: ⁠⁠⁠https://forms.gle/oNQPY6bJx9yBDrmf7⁠⁠⁠ Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 20:42 Shed Bucket 29:48 Stop Me If You've Heard This One Before 36:46 Refusing To Watch Daughter 44:18 Break 46:22 Dogs Be Barking 48:40 CJ: Is It French? 1:04:40 LS Sound 1:06:01 LS Story 1:14:41 Spicy AI Usage At Work 1:31:42 Outro Story Links: My uncle had this in his secret shed i was disgusted because my girlfriend used her snot as lube during a bj DELETED AITAH for refusing to watch my daughter when we meet my husbands friend? Update: Had to report a coworker for filling our work ChatGPT with corn. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week Meghan is joined by actor, humorist, and six-time author Annabelle Gurwitch, who returns to the podcast to discuss her new memoir, The End of My Life Is Killing Me: The Unexpected Joys of a Cancer Slacker. Annabelle was diagnosed with stage IV lung cancer during COVID, entirely out of the blue, after what she assumed was a meaningless cough. Five years later, she remains an outlier on a targeted therapy that has kept her stable. In this conversation, Annabelle talks about how she has resisted the sentimental clichés surrounding illness, why she rejects the idea that cancer is a "battle," and how humor, contrarianism, and facing "the shipwreck of the soul" have shaped the way she lives now. Guest Bio: Annabelle Gurwitch is an actress, activist, and New York Times bestselling author of six books and two-time finalist for the Thurber Prize. Her essays have appeared in The New Yorker, New York Times, Washington Post, The Wall Street Journal, Boston Globe, and Hadassah Magazine, among other publications. Her six books include the New York Times bestseller and Thurber Prize finalist I See You Made an Effort. Annabelle co-hosted the fan favorite Dinner & a Movie on TBS, was a regular commentator for NPR. She is serving in leadership as a patient advocate with the International Association for the Study of Lung Cancer (IASLC).

Neuraxial analgesia (epidural or spinal) combined withtocolytic therapy is the pain control method that best increases the success rate of external cephalic version (ECV), according to the ACOG's PB 221. However, some patients may be reluctant to use regional anesthesia and may askabout IV analgesia. A new study in the AJOG (released as an ePub on March 5, 2026) provides some insights that may be helpful for patient consultation. These investigators compared the success of external cephalic version, modes of delivery, maternal pain, and complications using three strategies: intravenous analgesia with remifentanil, epidural anesthesia, and a stepwise approach in which epidural anesthesia was administered only if intravenous analgesia was unsuccessful. Listen in for details.1.     ACOG PB 2212.     Aiartzaguena, Amaia et al. Comparativeeffectiveness of intravenous remifentanil, epidural anesthesia and a two-stepanalgesic approach for external cephalic version: a large prospectivesingle-center cohort study. American Journal of Obstetrics & Gynecology,Volume 0, Issue 03.     Hao Q, Hu Y, Zhang L, et a l. A SystematicReview and Meta-Analysis of Clinical Trials of Neuraxial, Intravenous, andInhalational Anesthesia for External Cephalic Version. Anesthesia andAnalgesia. 2020. 4.     Wilson MJA, MacArthur C, Hewitt CA, et al.5.     Intravenous Remifentanil Patient-ControlledAnalgesia Versus Intramuscular Pethidine for Pain Relief in Labour (RESPITE):An Open-Label, Multicentre, Randomised Controlled Trial. Lancet. 2018.

Meditación sobre el Evangelio del martes de la IV semana de Cuaresma: la curación del paralítico al que Jesús dice: "Levántate, toma tu camilla y anda". Nos lo dice a nosotros: levántate, deja lo que te detiene para hacer el bien, esfuérzate. Toma tu camilla: acepta tu responsabilidad. Y echa a andar: ve al mundo y a los demás con coraje, tratando de hacer sus vidas y el mundo mejor.

This week, Tee welcomes Caleb Granger, the founder and President of Apex Medical, to explore the emerging science behind stem cell-derived exosomes and their potential role in healing, regeneration, and longevity. Caleb explains that many forms of chronic decline are not simply the result of aging, but of reduced cellular communication and diminished regenerative signaling in the body. Caleb breaks down the science behind exosomes, which are nano-sized particles released by stem cells that carry proteins, growth factors, and biological instructions that help coordinate repair and healing across tissues and organs. Drawing on more than 25 years of experience working on the business side of spine, neurosurgery, orthopedic surgery, and medical device innovation, Caleb explains the difference between stem cell therapy and exosome therapy. Much of the healing potential associated with stem cells comes from the signals they release rather than the cells themselves. Because exosomes are acellular, they cannot replicate or transfer full genetic information, which many researchers believe may make them a safer way to deliver regenerative signals. Tee and Caleb also discuss how exosomes are sourced from donated placental and umbilical tissue, and screened rigorously to maintain the highest safety standards. The conversation also explores how exosome therapies may help address systemic inflammation and support recovery in conditions such as joint degeneration, cartilage damage, tendon and ligament injuries, neurological conditions, tinnitus, and metabolic disorders like type 2 diabetes. Caleb also shares insights on delivery methods, including IV therapy and injections, and explains why these therapies remain largely outside traditional insurance coverage and how he and his team are looking to change that! Connect with Caleb and Apex Medical:  Website LinkedIn Instagram TikTok   Follow Therese "Tee" Forton-Barnes and The Green Living Gurus: Austin Air Purifiers: For podcast listeners, take 15% off any Austin Air product; please email Tee@thegreenlivinggurus.com and mention that you want to buy a product and would like the discount. See all products here: Austin Air The Green Living Gurus' Website  Instagram YouTube Facebook Healthy Living Group on Facebook Tip the podcaster! Support Tee and the endless information that she provides: Patreon Venmo: @Therese-Forton-Barnes last four digits of her cell are 8868 For further info, contact Tee: Email: Tee@thegreenlivinggurus.com Cell: 716-868-8868 DISCLAIMER: ALL INFORMATION PROVIDED HERE IS GENERAL GUIDANCE AND NOT MEANT TO BE USED FOR INDIVIDUAL TREATMENT. PLEASE CONTACT YOUR PROVIDER OR DOCTOR FOR MEDICAL ADVICE. Produced By: Social Chameleon

Hoy en ¡Ya Párate!... Scrolleando … Lo que no sabías que sabías … Operación dejando a la bendi … “Lavando Ajeno”… Clases de ligue con Leopi... y Deportes con Iván el Pollo Elizondo...

En Columnistas de Mesa Central, Iván Valenzuela y Kike Mujica conversaron con María José Naudon y Lucía Dammert sobre los costos políticos de ejecutar indultos presidenciales, tras los dichos del Presidente José Antonio Kast.

Today we begin an extended series on the gospel of Mark, a document that reveals the story of Jesus Christ and His first followers. Jesus stands at the very center of history's stage. He has no equals; He has no peers. Let's examine four aspects of this unique book.I. The Presentation of Jesus (“The beginning”)II. The Proclamation of Jesus (“The gospel”)III. The Person of Jesus (“Jesus Christ the Son of God”)IV. The Prediction of Jesus (“As it is written in the Prophets”)Talk with God: Meditate on Ephesians 1:7 and spend time in worship thanking the Lord for His faithfulness to redeem.Talk with others: Invite your friends and family to join you for Easter Sunrise service.Talk with kids: How was Ahab disobedient, stubborn, and greedy?

Welcome to What Matters Now, a weekly podcast exploring key issues currently shaping Israel and the Jewish World, with host Amanda Borschel-Dan speaking with Bret Stephens, a The New York Times columnist and the editor-in-chief of Sapir magazine. Recent polling indicates that only roughly half of Americans support the US-Israel war against Iran's Islamist regime. Stephens weighs in on why the current conflict can be both "Trump's war" and a just war. Far from feeling that Israel dragged the US into this war, he says that for the first time in recent history, the US has a partner with whom to wage a war. "This war is different, not because it's a war for Israel. It's a war with Israel," says Stephens. But is the American public capable of internalizing the Iranian regime as an existential threat? In answer, Stephens asks whether a patient with stage II cancer should be advised to wait to treat it until it develops into stage IV. "Thank goodness we're acting now rather than just waiting on events," says Stephens. Assessing today's global dynamics and the authoritarian axis of Iran, Russia, North Korea and China, he turns to the 1930s, when the world was experiencing a series of conflicts that eventually led to World War II. He warns there is no Hollywood ending in sight. And so this week, we ask Bret Stephens, what matters now. What Matters Now podcasts are available for download on Apple Podcasts, Spotify, YouTube or wherever you get your podcasts. This episode was produced by Gabriella Jacobs and edited by Ari Schlacht. IMAGE: New York Times columnist Bret Stephens (YouTube screenshot) / Beirut, Lebanon, March 15, 2026. (AP Photo/Hassan Ammar)See omnystudio.com/listener for privacy information.

going to reupload some older stuff while i figure out what i'm doingStory by HeguenDmerak⁠https://nightscribe.co/u/69781/heguendmerak⁠Timestamps:I. New Comer (0:00 - 9:57)II. Survival Guide (9:57 - 20:37)III. Be Afraid of the Dark (20:37 - 29:45)IV. Five Minutes of Fame (29:45 - 42:18)V. Learning (42:18 - 53:52)VI. Double Standard (53:52 - 1:04:33)VII. Bad Attitude (1:04:33 - 1:14:12)VIII. Veterans (1:14:12 - 1:24:05)IX. The Greater Good (1:24:05 - 1:33:50)X. Bound to Happen (1:33:50 - 1:44:31)XI. Doing Business (1:44:31 - 1:53:18)XII. Memories (1:53:18 - 2:07:21)XIII. A Battery (2:07:21 - 2:16:15)XIIII. Debauchery (2:16:15 - 2:25:28)XV. Cheating Death (2:25:28 - 2:43:25)Epilogue. (2:43:25 - 2:48:05)

Meditación acerca de la oración colecta y el Evangelio de la misa del lunes IV de Cuaresma, en el que el Señor cura al hijo del funcionario real de Cafarnaún. Debemos rezar y ayunar por los más indefensos: los pobres. Y tener fe en que Dios cerca de nosotros, nos escucha y puede obrar milagros a distancia.

LAUDES DOMINGO DE LA IV SEMANA DE CUARESMA(Oración de la mañana) - IV semana del SalterioINVOCACIÓN INICIALV. Señor abre mis labiosR. Y mi boca proclamará tu alabanzaINVITATORIOAnt. A Cristo, el Señor, que por nosotros fue tentado y por nosotros murió, venid, adorémosle.SALMODIASalmo 117 - Ant. Tú eres mi Dios, te doy gracias; Dios mío, yo te ensalzo.Cántico - Ant. Capaz eres, Señor, de liberarnos de la mano del poderoso; líbranos, Señor, Dios nuestro.Salmo 150 - Ant. Alabad al Señor por sus obras magníficas.RESPONSORIO BREVE V. Cristo, Hijo de Dios vivo, ten piedad de nosotros.R. Cristo, Hijo de Dios vivo, ten piedad de nosotros.V. Tú que estas sentado a la derecha del Padre.R. Ten piedad de nosotros.V. Gloria al Padre, y al Hijo, y al Espíritu Santo.R. Cristo, Hijo de Dios vivo, ten piedad de nosotros.CÁNTICO EVANGÉLICOAnt. Padre, he pecado contra ti, ya no merezco ser hijo tuyo.Cántico de Zacarías. EL MESÍAS Y SU PRECURSOR      Lc 1, 68-79Bendito sea el Señor, Dios de Israel,porque ha visitado y redimido a su pueblo.suscitándonos una fuerza de salvaciónen la casa de David, su siervo,según lo había predicho desde antiguopor boca de sus santos profetas:Es la salvación que nos libra de nuestros enemigosy de la mano de todos los que nos odian;ha realizado así la misericordia que tuvo con nuestros padres,recordando su santa alianzay el juramento que juró a nuestro padre Abraham.Para concedernos que, libres de temor,arrancados de la mano de los enemigos,le sirvamos con santidad y justicia,en su presencia, todos nuestros días.Y a ti, niño, te llamarán Profeta del Altísimo,porque irás delante del Señora preparar sus caminos,anunciando a su pueblo la salvación,el perdón de sus pecados.Por la entrañable misericordia de nuestro Dios,nos visitará el sol que nace de lo alto,para iluminar a los que viven en tinieblay en sombra de muerte,para guiar nuestros pasospor el camino de la paz.Gloria al Padre, y al Hijo, y al Espíritu Santo.Como era en el principio, ahora y siempre, por los siglos de los siglos. Amén.PRECES“Enciende, Señor, en nosotros la llama de tu amor.”ConclusionV. El Señor nos bendiga, nos guarde de todo mal y nos lleve a la vida eterna.R. Amén.(149)

Welcome to What Matters Now, a weekly podcast exploring key issues currently shaping Israel and the Jewish World, with host Amanda Borschel-Dan speaking with Bret Stephens, a The New York Times columnist and the editor-in-chief of Sapir magazine. Recent polling indicates that only roughly half of Americans support the US-Israel war against Iran's Islamist regime. Stephens weighs in on why the current conflict can be both "Trump's war" and a just war. Far from feeling that Israel dragged the US into this war, he says that for the first time in recent history, the US has a partner with whom to wage a war. "This war is different, not because it's a war for Israel. It's a war with Israel," says Stephens. But is the American public capable of internalizing the Iranian regime as an existential threat? In answer, Stephens asks whether a patient with stage II cancer should be advised to wait to treat it until it develops into stage IV. "Thank goodness we're acting now rather than just waiting on events," says Stephens. Assessing today's global dynamics and the authoritarian axis of Iran, Russia, North Korea and China, he turns to the 1930s, when the world was experiencing a series of conflicts that eventually led to World War II. He warns there is no Hollywood ending in sight. And so this week, we ask Bret Stephens, what matters now. What Matters Now podcasts are available for download on Apple Podcasts, Spotify, YouTube or wherever you get your podcasts. This episode was produced by Gabriella Jacobs and edited by Ari Schlacht. IMAGE: New York Times columnist Bret Stephens (YouTube screenshot) / Beirut, Lebanon, March 15, 2026. (AP Photo/Hassan Ammar)See omnystudio.com/listener for privacy information.

Bernie Miklasz joins Tom Ackerman on Sports on a Sunday Morning to discuss the Cardinals' spring training storylines in Jupiter. They talk about Oli Marmol's push for transparency and collaboration within the organization, Jordan Walker stepping away from games to work in the hitting lab, and the roster competition in the outfield. Bernie also breaks down Victor Scott II's improved bat speed, the impact of prospects like Thomas Saggese and JJ Wetherholt, and concerns about Iván Herrera's health heading toward Opening Day

Niko Moreno joins Jeremiah to discuss the 0-3 Sounders win at Vancouver in Leg 1 of their Concacaf Champions Cup tie, and they talk about Paul Arriola who started for the first time in over a year (knee injury) and helped secure the victory with a brace. They also talk about one of the key players in this matchup - Jesus Ferreira - and how his phenomenal outing helped the team tremendously. The two round it up by discussing the upcoming San Jose matchup and what will most likely be a very rotated lineup.Follow Niko Moreno on BlueSky and YouTube.Sponsor

Niko Moreno joins Jeremiah to discuss the 0-3 Sounders win at Vancouver in Leg 1 of their Concacaf Champions Cup tie, and they talk about Paul Arriola who started for the first time in over a year (knee injury) and helped secure the victory with a brace. They also talk about one of the key players in this matchup - Jesus Ferreira - and how his phenomenal outing helped the team tremendously. The two round it up by discussing the upcoming San Jose matchup and what will most likely be a very rotated lineup.Follow Niko Moreno on BlueSky and YouTube.Sponsor

Las autoridades cubanas confirmaron que sostienen un diálogo con la administración de Donald Trump, que hasta ahora ha aplicado una política de presión máxima sobre el régimen castrista. Un reviro observa el profesor de relaciones internacionale de la Universidad Internacional de la Florida, Eduardo Gamarra ha atendido a RFI. Cuba confirmó este viernes que mantiene conversaciones con Estados Unidos, mientras inició la excarcelación de presos políticos como parte de un acuerdo con el Vaticano, el histórico mediador entre los dos países.  Esas conversaciones buscan "soluciones por la vía del diálogo a las diferencias bilaterales", precisó Díaz-Canel. La isla está sumida en una grave crisis de abastecimiento de combustible desde que no puede contar con el envío de petróleo de Venezuela, pero en el caso de Cuba, la administración republicana evitó la vía militar  y privilegia el diálogo. Un "reviro" observa el profesor de Relaciones internacionales de la Universidad Internacional de la Florida, Eduardo Gamarra  quien ha atendido a RFI. "Los republicanos históricamente llamaban a todos aquellos que buscaban el diálogo con Cuba hacia una transición. Los denominaban despectivamente como dialogueros, inclusive si nos acordamos, esos diálogos llevaron a un acuerdo entre la administración del presidente Obama y el régimen de Cuba. El contenido de los diálogos no lo sabemos en detalle, más allá de lo que Estados Unidos nos ha dicho, que es que el diálogo está encaminado a un cambio económico para de alguna manera levantar algunas de las sanciones" dice Gamarra.  Aún ignoramos los detalles de estos diálogos, pero La Habana inició la excarcelación de presos políticos y anunció la liberación de 51 de ellos. ¿Qué concesiones podría hacer el gobierno cubano? Responde Eduardo Gamarra. "No sabemos exactamente cuántos presos políticos hay en Cuba, pero se supone que son más de 1000. Se anunció que 56 creo que han sido liberados. Una señal de parte de Cuba, la señal positiva sería la liberación de los presos políticos, número uno. Número 2, pero que quizás número uno es el cambio económico, no la apertura de Cuba a reformas económicas. y sobre todo la presencia de Estados Unidos en el ámbito económico. Esa es la dimensión que es más importante en este momento para Washington. Los cambios políticos como tales. Si el modelo del CI es el modelo que están intentando perseguir, entonces no sabemos pues quién es el Del CI o la Del CI de Cuba, pero estarán buscando a alguien con quien entablar ese diálogo. El diálogo hasta ahora, Lo que nos han dicho públicamente es que ha sido con el nieto de Raúl Castro. Yo no tengo pues la información desde adentro, pero me imagino que Estados Unidos está buscando alguien con quien cogobernar Cuba en un proceso de transición" dice Gamarra en RFI.   Según Díaz-Canel, los intercambios con Estados Unidos fueron facilitados por "factores internacionales", que no precisó.    El jueves, su gobierno había anunciado la liberación anticipada de 51 prisioneros como muestra de "buena voluntad" hacia el Vaticano.    Las primeras excarcelaciones tuvieron lugar este viernes. La AFP asistió a la llegada a su casa de Adael Leyva Díaz, de 29 años y quien cumplía una condena de 13.  También a la de Ronald García Sánchez, de 33 años, sentenciado a 14 años, y vecino de Díaz, en el municipio de Arroyo Naranjo, al sur de la capital. Ambos participaron en las históricas protestas antigubernamentales que sacudieron la isla el 11 de julio de 2021.Leyva Díaz, que llegó en un triciclo eléctrico, fue recibido en plena calle por sus familiares. Tan pronto descendió del vehículo abrazó y cargó a su hijo. "Ya te tengo aquí, se acabó el sufrimiento", le dijo al abrazarlo su madre Ivón Díaz.

#Bàigiảng của Lm #IgnatioHồVănXuân trong thánh lễ Chúa nhật IV mùa Chay năm A, cử hành lúc 17:30 ngày 14-3-2026 tại Nhà thờ Chính Tòa Đức Bà #TGPSG

Is Medical Assistance in Dying (MAiD) in Canada really peaceful? This video breaks down the actual drug protocol used in MAiD procedures, the reported complication rates, and what the pharmacology data reveals about how assisted dying works in practice.Canada presents MAiD as clinical, controlled, and dignified. But when you examine the medications used — midazolam, propofol, neuromuscular blockers like rocuronium, and in some cases cardiotoxic drugs — the timeline and reported complications raise important questions.In this analysis, we cover:• The standard MAiD drug protocol in Canada• Median time to death and why it varies• Reported MAiD complications (including IV failures)• The role of paralytics in assisted dying• How cardiotoxic drugs induce cardiac arrest• Documentation gaps in MAiD reporting• Whether MAiD is as predictable as publicly describedThis is not a political debate. It is a close look at the medical mechanics behind physician-assisted death in Canada.If MAiD is now part of Canadian healthcare, transparency about the drugs, training, and outcomes matters. - - - - - - - - - - - -One Time Donation! - Paypal - https://paypal.me/brassandunityBuy me a coffee! - https://buymeacoffee.com/kelsisherenLet's connect!Youtube - https://www.youtube.com/@thekelsisherenperspectiveInstagram -  https://www.instagram.com/thekelsisherenperspective?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw%3D%3DX: https://x.com/KelsiBurnsInstagram: https://www.instagram.com/kelsie_sheren/Substack:  https://substack.com/@kelsisherenSUPPORT OUR PEOPLE - - - - - - - - - - - -MasterPeace - 10% off with code KELSI - https://www.MasterPeace.Health/KelsiKetone IQ- 30% off with code KELSI - https://ketone.com/KELSIGood Livin - 20% off with code KELSI - https://www.itsgoodlivin.com/?ref=KELSIBrass & Unity - 20% off with code UNITY  - http://brassandunity.com

In this episode of the How to Hyperbaric Podcast, Dr. Masha Makeeva speaks with integrative medicine expert Dr. Paul Anderson about one of the most common questions patients ask when using hyperbaric oxygen therapy: Can supplements be combined with HBOT without reducing its benefits?You'll discover:• Whether supplements or antioxidants can interfere with hyperbaric oxygen therapy• The key difference between oral supplements and IV nutrients when used with HBOT• The foundational supplements Dr. Anderson most often recommends for patients • How molecular hydrogen may support recovery and chronic illness• Why combining too many therapies at once can sometimes overwhelm the body instead of helping it healThis conversation also challenges a common belief in modern wellness culture: that the more therapies you stack, the better the results. But what if the opposite is sometimes true? Dr. Anderson explains why combining too many treatments can quietly overwhelm the body and how to choose therapies you actually need.

Födslotalen dyker i Europa och varför det fortsätter nedåt är en gåta. Vad händer när den europeiska bebiskollapsen blir politik? Lyssna på alla avsnitt i Sveriges Radios app. I land efter land i Europa dyker siffrorna över antalet nyfödda. Demografer famlar efter förklaringar och medan avsaknaden av säkra svar är ett faktum dras nya politiska konfliktlinjer upp. Hör om hur radikalhögern i Europa vill äga befolkningsfrågan och hur Ungerns Viktor Orbán gått fram med en familjepolitik som andra ytterhögerpartier nu tar efter. Däribland AFD i Tyskland, som genom engångsutbetalningar vill uppmuntra kvinnor att föda fler barn. Inte sällan ställs migration mot inhemskt barnafödande och Spanien går mot strömmen när invandrare ses som en framtidslösning. Även i Sverige har befolkningsfrågan hamnat på den politiska dagordningen. I Västerbottens inland söker Konflikt svar på hur framtiden kan se ut och vad som står på spel för våra samhällen.Medverkande: Pieter Vanhuysse, demograf och ekonom vid Syddansk Universitet. Vanessa Behrendt, familjepolitisk talesperson för AFD i Niedersachsen. Weiard Siebels, SPD-politiker i Niedersachsen. Onalia Bueno, borgmästare i Mogán på Kanarieöarna. Cecilia Festin Stenlund (L), kommunalråd i Malå. Tove Lestander, förälder i Sorsele. Marie Quinonez Gonzalez, kommunchef i Sorsele. Pia Sjöberg (S), kommunalråd i Sorsele. Jakob Forssmed (KD), socialminister. Invånare i Hannover, Tyskland samt i Sorsele, Sverige.Reporter i Spanien: Daniel Ekblad, frilansjournalist.Producent och reporter i Västerbotten: Therese Rosenvingetherese.rosenvinge@sverigesradio.seProgramledare och reporter i Hannover: Filip Kotsambouikidisfilip.kotsambouikidis@sverigesradio.seTekniker: Lisa Abrahamsson

Sobre los desafíos energéticos de la ministra Ximena Rincón y los nombres clave que llegan a las instituciones dependientes del Ministerio de Culturas, encabezado por Francisco Undurraga, Iván Valenzuela conversó con las editoras Paloma Ávila y Paula Escobar Chavarría en un nuevo Rat Pack de Mesa Central.

Happy accidents, the gear that's always moving, and bluegrass Outkast. Jimmy James (Parlor Greens, True Lovers) PARLOR GREENS- Emeralds [RELEASE DATE: 4/10/2026]- https://www.coleminerecords.com "Listening to the abundant sounds of the Seattle-based funk & soul group, True Loves, is like walking down a favorite neighborhood street, slapping five with friends, checking up with clerks in their stores, and smelling the familiar scents of your most cherished locale. The band is its own block party. ‌What began in 2014 as a jam session between three of the city's best - drummer David McGraw, bassist Bryant Moore, and guitarist Jimmy James - has since blossomed into a global force that features percussionist Iván Galvez, trombonist Greg Kramer, and saxophonists Gordon Brown and Skerik. Together, the group's live performances have garnered them much acclaim and millions of streams on YouTube. ‌In 2017, True Loves recorded their debut instrumental LP, Famous Last Words, which received worldwide adulation, earning them performances at coveted music festivals. In 2018, the group released the "Dapper Derp/Kabuki" 45' on WeCoast Records followed by 2019's Colemine Records "Famous Last Words/Mary Pop Poppins" 45 single. The band released their sophomore album "Sunday Afternoon" in 2021, on Color Red Music. 2024 saw the band release their latest "Good Weed and Red Wine" followed by their second European tour. A second single, "Dopus No. 1" was released in January 2025 with a vinyl 7" release of both songs on Valentine's day." Excerpt from https://www.truelovesband.com/about Parlor Greens: Bandcamp: https://parlorgreens.bandcamp.com Instagram: @parlorgreens Website: https://www.parlorgreens.com/ Merch: https://www.hellomerch.com Records: https://www.coleminerecords.com True Loves: Bandcamp: https://truelovesband.bandcamp.com Instagram: @truelovesband Website: https://www.truelovesband.com Merch: https://truelovesband.bandcamp.com/merch Records: https://www.truelovesband.com/music The Vineyard: Instagram: @thevineyardpodcast Website: https://www.thevineyardpodcast.com Youtube: https://www.youtube.com/@thevineyardpodcast

En Columnistas de Mesa Central, Iván Valenzuela conversa con Daniel Mansuy y Jorge Navarrete sobre los primeros días del Presidente José Antonio Kast en La Moneda y el uso de la facultad para indultar.

John Muller of Futi.live joins Jeremiah to talk about his new app, Futi which aims to go beyond other similar scoring or statistical apps. They discuss the technical foundations and data sources of the application, as well as the advanced models and new stylistic models being introduced. The two also analyze the Sounders style of play through the lens of the Futi data.Follow John Muller on BlueSky and the Futi.live.Sponsor

John Muller of Futi.live joins Jeremiah to talk about his new app, Futi which aims to go beyond other similar scoring or statistical apps. They discuss the technical foundations and data sources of the application, as well as the advanced models and new stylistic models being introduced. The two also analyze the Sounders style of play through the lens of the Futi data.Follow John Muller on BlueSky and the Futi.live.Sponsor

La senadora Aida Quilcué, fórmula vicepresidencial del candidato Iván Cepeda, habló en 6AM W sobre la campaña y su trabajo como defensora de derechos humanos.

Descubre Cómo Entender de Verdad Un Trastorno de Ansiedad y Tomar Acción En Nuestro Curso Gratuito El Mapa de La Ansiedad: https://escuelaansiedad.com/Cursos/el-mapa-de-la-ansiedad Descripción para YouTube En este vídeo de AMADAG TV hacemos un recorrido histórico por uno de los enfoques más influyentes de la psicología moderna: el conductismo. A través de una explicación clara, práctica y accesible, exploramos cómo la psicología fue dejando atrás una tradición más filosófica e introspectiva para convertirse en una disciplina cada vez más cercana al método científico, centrada en la observación, la medición y el análisis de la conducta humana. Durante mucho tiempo, gran parte de la psicología estuvo ligada a preguntas sobre la mente, la conciencia y la experiencia interna. Sin embargo, estas cuestiones planteaban un problema importante: resultaban difíciles de medir de forma objetiva. En ese contexto surge el conductismo como una propuesta revolucionaria. El autor del texto utiliza una analogía muy poderosa: la del ingeniero del comportamiento, alguien que no trabaja con especulaciones invisibles, sino con datos observables, variables concretas y relaciones funcionales entre lo que ocurre en el entorno y la respuesta de las personas. En este contenido repasamos los pilares esenciales del conductismo, comenzando por Iván Pávlov y sus experimentos sobre el condicionamiento clásico, que demostraron cómo un organismo puede aprender asociaciones entre estímulos. También abordamos las investigaciones de Edward Thorndike, fundamentales para comprender cómo el comportamiento cambia en función de sus consecuencias, especialmente a través de su conocida ley del efecto. Por supuesto, analizamos también el papel decisivo de John B. Watson, considerado uno de los grandes impulsores del conductismo. Watson defendió que la psicología debía abandonar el estudio de la mente como entidad invisible y concentrarse en algo mucho más verificable: predecir y controlar la conducta observable. Su propuesta marcó un antes y un después, redefiniendo el rumbo de la disciplina y abriendo la puerta a nuevas formas de entender el aprendizaje, el ambiente y la adaptación humana. Pero este vídeo no se queda en la historia. También reflexionamos sobre cómo estos mecanismos siguen plenamente vigentes en la actualidad, especialmente en la era digital. Hoy vivimos rodeados de estímulos, recompensas inmediatas, señales, hábitos y asociaciones que influyen constantemente en nuestras decisiones. Desde el uso del móvil hasta las redes sociales, pasando por nuestros miedos, rutinas y formas de actuar, el entorno sigue moldeando nuestra conducta muchas veces sin que nos demos cuenta. Comprender estas bases no solo es útil para conocer mejor la historia de la psicología, sino también para observarnos con más profundidad. Entender cómo aprendemos, cómo se refuerzan ciertas respuestas y cómo se consolidan determinados patrones puede ayudarnos a intervenir con mayor conciencia en nuestra vida. Y cuando hablamos de ansiedad, hábitos, evitación o aprendizaje emocional, esta comprensión se vuelve todavía más valiosa. Si te interesa la psicología, el aprendizaje, la conducta humana y su impacto en la ansiedad, este vídeo puede darte una base sólida para mirar tu comportamiento desde una perspectiva diferente, más clara y más práctica. Títulos alternativos 4 claves del conductismo que van a ayudarte a entender por qué actúas como actúas Llevas años entendiendo mal la psicología: así cambió todo con el conductismo Esta manera de entender la conducta puede cambiar tu forma de ver la ansiedad para siempre 5 cosas que nunca te contaron sobre el conductismo y cómo moldea tus decisiones De Pávlov a las redes sociales: el experimento invisible que sigue guiando tu conducta Keywords conductismo, historia del conductismo, psicología conductista, condicionamiento clásico, iván pávlov, pavlov psicología, edward thorndike, ley del efecto, john b watson, conducta observable, aprendizaje por asociación, refuerzo y castigo, análisis funcional de la conducta, psicología científica, conducta humana, historia de la psicología, psicología empírica, comportamiento humano, estímulo y respuesta, condicionamiento en psicología, bases del conductismo, entorno y conducta, hábitos y aprendizaje, ansiedad y conducta, amadag tv #️⃣ Hashtags #Conductismo, #Psicologia, #Pavlov, #JohnWatson, #Aprendizaje, #AMADAGTV Enlaces Nuestra escuela de ansiedad: www.escuelaansiedad.com Nuestro nuevo libro: www.elmapadelaansiedad.com Visita nuestra página web: http://www.amadag.com Facebook: https://www.facebook.com/Asociacion.Agorafobia/ Instagram: https://www.instagram.com/amadag.psico/ ▶️ Youtube Amadag TV: https://www.youtube.com/channel/UC22fPGPhEhgiXCM7PGl68rw

Sobre los detalles inéditos en torno a la cena familiar en Cerro Castillo del proclamado Presidente Kast y los contrastes simbólicos en La Moneda respecto a la administración Boric, Angélica Bulnes e Iván Valenzuela conversaron con las editoras Paula Comandari y Andrea Vial en un nuevo Rat Pack de Mesa Central.

In this episode, we go over the Joshcars aka the Rickelodean Teen Choice Awards aka the ESPissPees aka the BAFTAS but the A stands for Aurora as voted on by our fans! This episode is brought to you by: Jones Road Beauty! Go to JonesRoadBeauty.com and use code JUDGIES for a FREE shimmer face oil with your purchase! Want fun, cool stickers and MORE? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.aurorascreaturecorner.store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Palestine Children's Relief Fund⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Donation Link Edited by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@currentlyblinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/currentlyblink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tiktok.com/@currently.blinking⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Our Patreon is officially open, if you want to see extra content go check it out!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/JudgiesPod ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Send us mail! (Addressed However You'd Like)  P.O. Box 58 Ottawa, IL 61350  Leave a Review!  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://podcasts.apple.com/us/podcast/the-judgies/id1519741238⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow us on Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/judgiespod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Intro Music by: Iván  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/artist/5gB2VvyqfnOlNv37PHKRNJ?si=f6TIYrLITkG2NZXGLm_Y-Q&dl_branch=1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Time Stamps: 0:00 Intro 5:46 The Most Judgie 8:43 Funniest Reddit Story 11:18 Funniest Listener Story 12:59 I Hate People 15:03 The People's Champ 17:38 Best Circle Jerdge 21:59 That's Crazy 25:12 That's Crazy, Listener 27:37 Best Tangent 30:58 The 4th Judgie 36:45 The Unlistenable 44:12 Career In Music 46:06 Legally Not Advice Voicemail 47:42 Legally Not Advice Live Call 49:54 The Jerdge Us 52:25 Christian Coded 54:43 The Cherd 56:28 Chomped My Bit 59:07 Judgies Curse 1:00:57 Too Many Tangents 1:05:43 The Actually Hert Turk 1:08:42 The Cool 1:11:26 The Favorite Judgie 1:13:29 Closing Remarks Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's VETgirl online veterinary continuing education podcast, we review new 2025 data on hyperkalemia management in blocked cats and whether insulin-dextrose, bicarbonate, or beta2-agonists outperform IV fluids in reducing serum potassium and creatinine 4 hours post-treatment. Tune in for a quick breakdown of what these findings mean for your real-world blocked cat-protocols.

I. Jesus People GrowII. Jesus People GatherIII. Jesus People GiveIV. Jesus People GoTalk with God: Ask the Lord to show you the areas of your life in which you can be a better reflection of Jesus.Talk with others: Intentionally lift up the Jesus People around you and look for one practical way to come alongside someone walking through a difficult season this week.Talk with kids: How do we know God hears us when we pray?

Dopeywood 2 Tickets: https://www.showclix.com/event/dopeywood-2026 LISTEN WITHOUT ADS: www.patreon.com/dopeypodcast This week on "Dopey's Greatest Hits" replay of episode 240 with Jessica Kent (prison YouTuber and recovering addict), recorded during the early pandemic from Dave's attic. Dave opens with current (2020-era) updates: promoting an upcoming Dopey Wood 2 comedy show in LA (featuring Marc Maron, Bobby Lee, Margaret Cho, etc.), the Dopey Foundation, Patreon perks, free Narcan/test strips offers, and the ongoing Dopey sticker contest. He reads recent Spotify comments praising/recapping previous episodes (Brace Belden, nitrous stories, etc.), plays a listener voicemail about teenage nitrous abuse, then transitions into the main replay. The core interview covers Jessica Kent's life: early alcohol/pill use starting at ~12–13 in upstate New York, progression to IV heroin at 17, selling drugs (weed → heroin → meth), magazine subscription sales crews while on the run, $30k+ dealer debts, robberies by partners, running from charges, accidental meth introduction in Arkansas, pregnancy and arrest (3 weeks pregnant, 2 oz meth + gun charge), giving birth in prison while in leg chains, fighting for custody of her daughter Micah post-release, white-knuckle sobriety driven by DHS requirements/hair-follicle tests, eventual full custody, and building a new life (YouTube, podcast, degree). She describes prison violence (fights over petty things like 50¢ pizza sauce, beating a child sex offender), disdain for 12-step culture in her experience, identity crisis after getting clean, and how motherhood became her anchor (not 12 steps or traditional recovery programs). Dave closes with his father (the recurring "sweet father" segment) reading iTunes reviews, kvelling over rankings, discussing privilege critiques, financial responsibility in recovery, and playing Bob Forrest's “Comfortably Numb” cover + “Good So Bad” to end. ALL THAT MORE MORE MORE on the newest Old replay episode of that good old dopey show... Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.